Treats symptomatic tenosynovial giant cell tumor (TGCT). NDA 220414, held by EMD Serono. Pimicotinib.
As of Nov 21, 2026, NDA 220414 (Pimjetmi), held by EMD Serono, was first approved by FDA on Nov 10, 2026, with 0 approved supplements and 0 published complete response letters.
PIMJETMI is indicated for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection may cause worsening functional limitations or severe morbidity.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 10, 2026 | Original applicationNew molecular entity · Standard review | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Pimjetmi50MG · capsule; oral | Pimicotinib | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters